Foley Hoag lawyers and specialists provide leading innovative life science clients with strategic government affairs and business counseling on Federal acquisitions and procurements, and regulatory and legislative strategy, in the field of biodefense and pandemic preparedness. The core strength of Foley Hoag’s Biodefense and Pandemic Preparedness practice is the expertise of our lawyers and specialists, most of whom have extensive government experience. Our team has served in senior-level positions on Capitol Hill, regulatory agencies, and at industry trade associations.
Publications more
- National Biodefense Science Board Presents Recommendations [Read More]
- Foley Hoag Co-Hosts Congressional Briefing on Biodefense [Read More]
- Government Asked to Provide Certainty and Incentives for Countermeasure Development [Read More]
Client Successes more
-
Supplying the Nation with H1N1 Vaccine
In response to the significant demand last year for live H1N1 vaccines, Foley Hoag assisted leading biotechnology companies with securing contracts with the U.S. Department of Health and Human Services (HHS) to supply the H1N1 vaccine. These vaccines were approved by the U.S. Food and Drug Administration (FDA) and provided to health care facilities in advance and during the 2009 influenza season. Lawyers in the firm’s Life Sciences and Government Strategies practice, working as part of a specialized team focused on biodefense and pandemic issues, provide regulatory counsel from early product development to FDA approval, and through the Federal government procurement process.
[Read More]
-
Protecting the Nation Against Bioterrrorism
Foley Hoag lawyers in the Biodefense and Pandemic Preparedness practice regularly counsel clients on government affairs and business strategy in the development and distribution of products focused on medical countermeasures to terrorism and pandemics. Recently, the firm assisted a client, one of the Nation’s leading developers of effective countermeasures against biological and chemical weapons, in securing research and development funding for a second generation recombinant protective antigen (rPA) anthrax vaccine. The company may also be eligible to sell these critical products to the Federal Government under Project BioShield and authorities created as part of BARDA in 2008. Foley Hoag lawyers provide strategic government counseling and advocacy to secure support for these important biodefense countermeasures.
[Read More]